Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Predicting the impact of polypill use in a metabolic syndrome population: An effectiveness and cost-effectiveness analysis

    Access Status
    Fulltext not available
    Authors
    Zomer, E.
    Owen, A.
    Magliano, D.
    Ademi, Z.
    Reid, Christopher
    Liew, D.
    Date
    2013
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Zomer, E. and Owen, A. and Magliano, D. and Ademi, Z. and Reid, C. and Liew, D. 2013. Predicting the impact of polypill use in a metabolic syndrome population: An effectiveness and cost-effectiveness analysis. American Journal of Cardiovascular Drugs. 13 (2): pp. 121-128.
    Source Title
    American Journal of Cardiovascular Drugs
    DOI
    10.1007/s40256-013-0019-2
    ISSN
    1175-3277
    School
    Department of Health Policy and Management
    URI
    http://hdl.handle.net/20.500.11937/8893
    Collection
    • Curtin Research Publications
    Abstract

    Background: Individuals with metabolic syndrome (MetS) are at increased risk of cardiovascular disease (CVD), often requiring combination drug therapy for control of risk factors and subsequent risk reduction. This study aims to compare the long-term effectiveness and cost effectiveness of the polypill (a multi-component tablet), and its components (alone or in combination), in a MetS population. Methods and Results: A Markov state transition model, using individual subject data from the Australian Diabetes, Obesity and Lifestyle study, was constructed to simulate the effects of the treatment versus no treatment on CVD events, and costs over 10 years. In 1,991 individuals classified as MetS and free of existing diabetes mellitus or CVD, treatment with the polypill (or its components) was effective at reducing cardiovascular events [statin: 171, aspirin (actetylsalicylic acid): 201, antihypertensive: 186 per 1,000 individuals]. The more drug therapies employed the greater the reduction, with the polypill reducing up to 351 cardiovascular events per 10,000 individuals. Cost-effectiveness analyses were sensitive to drug treatment costs and effectiveness of treatment. At a cost of AUD$42 per person per annum, aspirin was considered cost saving. All other treatment strategies, including the polypill, were not cost effective. Conclusion: The polypill is likely to be effective in the reduction of cardiovascular events in a MetS population. It is, however, not cost effective. Nevertheless, in a high-risk population, among whom combination therapy is often prescribed, the polypill is likely to be more cost effective than antihypertensive therapy alone or dual therapy with a statin and antihypertensive combination. © 2013 Springer International Publishing Switzerland.

    Related items

    Showing items related by title, author, creator and subject.

    • The Effect of a Cardiovascular Polypill Strategy on Pill Burden.
      Truelove, M.; Patel, A.; Bompoint, S.; Brown, A.; Cass, A.; Hillis, G.; Peiris, D.; Rafter, N.; Reid, Christopher; Rodgers, A.; Tonkin, A.; Usherwood, T.; Webster, R.; Kanyini GAP Collaboration (2015)
      AIMS: Recent trials of cardiovascular polypills in high-risk populations show improvements in use of cardiovascular preventive treatments, compared to usual care. We describe patterns of pill burden in Australian practice, ...
    • Reaching cardiovascular prevention guideline targets with a polypill-based approach: A meta-Analysis of randomised clinical trials
      Selak, V.; Webster, R.; Stepien, S.; Bullen, C.; Patel, A.; Thom, S.; Arroll, B.; Bots, M.; Brown, A.; Crengle, S.; Dorairaj, P.; Elley, C.; Grobbee, D.; Harwood, M.; Hillis, G.; Laba, T.; Neal, B.; Peiris, D.; Rafter, N.; Reid, Christopher; Stanton, A.; Tonkin, A.; Usherwood, T.; Wadham, A.; Rodgers, A. (2019)
      Objective: The aim of this study was to determine the effect of polypill-based care on the achievement of 2016 European Society of Cardiology (ESC) guideline targets for blood pressure (BP), low-density lipoprotein (LDL) ...
    • Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: A randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk
      Liu, H.; Patel, A.; Brown, A.; Eades, S.; Hayman, N.; Jan, S.; Ring, I.; Stewart, G.; Tonkin, A.; Weeramanthri, T.; Wade, V.; Rodgers, A.; Usherwood, T.; Neal, B.; Peiris, D.; Burke, H.; Reid, Christopher; Cass, A. (2010)
      Background. The Kanyini Guidelines Adherence with the Polypill (Kanyini-GAP) Study aims to examine whether a polypill-based strategy (using a single capsule containing aspirin, a statin and two blood pressure-lowering ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.